Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3

NCT05052554 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No patients

Conditions

Fuchs Endothelial Corneal Dystrophy
FECD3
Corneal Diseases
LRS
Descemet's Membrane Disorder

Interventions

DRUG: QR-504a

Sponsor

ProQR Therapeutics